HealthInvest Partners’s Summit Therapeutics SMMT Stock Holding History

HealthInvest Partners’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-92,737	Closed	-$1.92M	–	46
2025 Q3	$1.92M	Hold	92,737	–	–	0.75%	34
2025 Q2	$1.97M	Sell	92,737 -12,340	-12%	-$281K	0.84%	32
2025 Q1	$2.03M	Buy	105,077 +3,900	+4%	+$78.2K	0.89%	29
2024 Q4	$1.31M	Buy	101,177 +15,164	+18%	+$294K	0.62%	30
2024 Q3	$1.88M	Buy	+86,013	New	+$1.2M	0.89%	26

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

PCMH

Polymer Capital Management (HK) Hong Kong $1.98B AUM 210.13% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

HealthInvest Partners's SMMT Position: Q4 2025 in Review

HealthInvest Partners sold out of Summit Therapeutics (SMMT) in Q4 2025, closing a stake of 92,737 shares — an estimated $1.92M sold.

HealthInvest Partners first reported a position in SMMT in Q3 2024 and held it in 5 quarters. The position peaked at $2.03M in Q1 2025. 206 funds tracked by Wall St. Rank hold SMMT as of Q4 2025.

HealthInvest Partners reported no remaining Summit Therapeutics position as of Q4 2025 after selling out during the quarter.
HealthInvest Partners sold 92,737 Summit Therapeutics shares in Q4 2025, an estimated $1.92M.
HealthInvest Partners first reported a position in Summit Therapeutics in Q3 2024 and held it in 5 quarters.
HealthInvest Partners's Summit Therapeutics position peaked at $2.03M in Q1 2025.
206 funds tracked by Wall St. Rank held Summit Therapeutics as of Q4 2025.

Based on HealthInvest Partners's 13F filing for Q4 2025, filed 6 Feb 2026.